| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 21 | | | |
| | | | 23 | | | |
| | | | 25 | | | |
| | | | 45 | | | |
| | | | 46 | | | |
| | | | 48 | | | |
| | | | 49 | | | |
| | | | 52 | | | |
| | | | 53 | | |
Name
|
| |
Age
|
| |
Position(s)
|
| |
Class
|
| |
Term Expires
|
|
Stuart A. Arbuckle(1)(2)
|
| |
57
|
| | Director | | |
I
|
| |
2024
|
|
Camille L. Bedrosian, M.D.(1)(3)
|
| |
70
|
| | Director | | |
III
|
| |
2023
|
|
Jennifer Good
|
| |
58
|
| | Director | | |
II
|
| |
2025
|
|
Christophe R. Jean(2)
|
| |
67
|
| | Director | | |
I
|
| |
2024
|
|
Edward T. Mathers(3)
|
| |
63
|
| | Lead Director | | |
II
|
| |
2025
|
|
David W. J. McGirr(2)(3)
|
| |
68
|
| | Director | | |
III
|
| |
2023
|
|
David P. Meeker, M.D.
|
| |
68
|
| |
Director, Chairman of the Board
|
| |
III
|
| |
2023
|
|
Lynn A. Tetrault, J.D.(1)
|
| |
60
|
| | Director | | |
I
|
| |
2024
|
|
|
Board Diversity Matrix (As of April 27, 2023)
|
| ||||||||||||
| Total Number of Directors | | |
8
|
|
| | |
Female
|
| |
Male
|
| |
Non-Binary
|
| |
Did Not
Disclose Gender |
| ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors
|
| | | | 3 | | | | | | 5 | | | | | | 0 | | | | | | 0 | | |
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | |
African American or Black
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Alaskan Native or Native American
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Asian
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Hispanic or Latinx
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Native Hawaiian or Pacific Islander
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
White
|
| | | | 3 | | | | | | 5 | | | | | | 0 | | | | | | 0 | | |
Two or More Races or Ethnicities
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
LGBTQ+
|
| |
0
|
| |||||||||||||||||||||
Did Not Disclose Demographic Background
|
| |
0
|
|
Name:
|
| |
Governance and
Nominating Committee |
| |
Compensation & Management
Development Committee |
| |
Audit
Committee |
|
Stuart A. Arbuckle
|
| | | | |
X
|
| |
X
|
|
Camille L. Bedrosian, M.D.
|
| |
X
|
| |
X
|
| | | |
Christophe R. Jean
|
| | | | | | | |
X
|
|
Edward T. Mathers
|
| |
X*
|
| | | | | | |
David W. J. McGirr
|
| |
X
|
| | | | |
X*
|
|
Lynn A. Tetrault, J.D.
|
| | | | |
X*
|
| | | |
Non-Employee Director
|
| |
Annual Fee
|
| |||
Lead Director
|
| | | $ | 35,000 | | |
Non-Executive Chair
|
| | | $ | 30,000 | | |
Chair of the Audit Committee
|
| | | $ | 20,000 | | |
Member of the Audit Committee (other than chair)
|
| | | $ | 10,000 | | |
Chair of the Compensation & Management Development Committee
|
| | | $ | 15,000 | | |
Member of the Compensation & Management Development Committee (other than chair)
|
| | | $ | 7,500 | | |
Chair of the Governance and Nominating Committee
|
| | | $ | 10,000 | | |
Member of the Governance and Nominating Committee (other than chair)
|
| | | $ | 5,000 | | |
Name
|
| |
Fees Earned
or Paid in Cash ($)(1) |
| |
Option
Awards ($)(2) |
| |
Total
($) |
| |||||||||
Stuart Arbuckle
|
| | | | 65,000 | | | | | | 53,400 | | | | | | 118,400 | | |
Camille Bedrosian, M.D.
|
| | | | 56,250 | | | | | | 53,400 | | | | | | 109,650 | | |
Jennifer Good
|
| | | | 47,500 | | | | | | 53,400 | | | | | | 100,900 | | |
Christophe R. Jean
|
| | | | 57,500 | | | | | | 53,400 | | | | | | 110,900 | | |
Edward T. Mathers
|
| | | | 92,500 | | | | | | 53,400 | | | | | | 145,900 | | |
David W. J. McGirr
|
| | | | 72,500 | | | | | | 53,400 | | | | | | 125,900 | | |
Lynn A. Tetrault
|
| | | | 62,500 | | | | | | 53,400 | | | | | | 115,900 | | |
Name
|
| |
Option Awards
Outstanding at 2022 Fiscal Year End |
| |
Unvested Stock
Awards Outstanding at 2022 Fiscal Year End |
| ||||||
Stuart Arbuckle
|
| | | | 83,500 | | | | | | — | | |
Camille Bedrosian, M.D.
|
| | | | 72,000 | | | | | | — | | |
Jennifer Good
|
| | | | 83,500 | | | | | | — | | |
Christophe R. Jean
|
| | | | 78,500 | | | | | | — | | |
Edward T. Mathers
|
| | | | 78,500 | | | | | | — | | |
David W. J. McGirr
|
| | | | 165,741 | | | | | | — | | |
Lynn A. Tetrault
|
| | | | 72,000 | | | | | | — | | |
Name
|
| |
Age
|
| |
Position(s)
|
|
David P. Meeker, M.D.
|
| |
68
|
| | Chairman of the Board, President and Chief Executive Officer | |
Hunter C. Smith
|
| |
55
|
| | Chief Financial Officer and Treasurer | |
Pamela Cramer
|
| |
49
|
| | Chief Human Resources Officer | |
Joseph Shulman
|
| |
48
|
| | Chief Technical Officer | |
Jennifer Chien
|
| |
48
|
| | Executive Vice President, Head of North America | |
Yann Mazabraud
|
| |
50
|
| | Executive Vice President, Head of International | |
|
What We Do
|
| |
What We Do Not Do
|
| ||||||
| ✓ | | | Emphasize performance-based, at risk compensation. | | | X | | | Do not grant guaranteed equity compensation. | |
| ✓ | | | Emphasize the use of equity compensation to promote executive retention and reward long-term value creation. | | | X | | | Do not provide significant perquisites. | |
| ✓ | | | Weight the overall pay mix towards incentive compensation for senior executives. | | | X | | | Do not provide any compensation-related tax gross-ups. | |
| ✓ | | | Engage an independent compensation consultant to advise our Compensation & Management Development Committee. | | | X | | | Do not reprice stock option awards issued under our 2017 Equity Incentive Plan without stockholder approval. | |
|
Agios Pharmaceuticals
|
| |
Deciphera Pharmaceuticals
|
| |
Intra-Cellular Therapies
|
| |
Travere Therapeutics
|
|
|
Akebia Therapeutics
|
| |
Epizyme
|
| |
Karyopharm Therapeutics
|
| |
Verastem
|
|
|
Albireo Pharma
|
| |
Esperion Therapeutics
|
| |
Ocular Therapeutix
|
| |
Vericel
|
|
|
Apellis Pharmaceuticals
|
| |
G1 Therapeutics
|
| |
Radius Health
|
| |
Zogenix
|
|
|
Cara Therapeutics
|
| |
Global Blood Therapeutics
|
| |
Rigel Pharmaceuticals
|
| | | |
|
ChemoCentryx
|
| |
Insmed
|
| |
TG Therapeutics
|
| | | |
|
Atara Biotherapeutics
|
| |
Dicerna Pharmaceuticals
|
| |
Magenta Therapeutics
|
| |
Syros Pharmaceuticals
|
|
|
Biohaven Pharmaceutical
|
| |
Iovance Biotherapeutics
|
| |
Odonate Therapeutics
|
| | | |
|
Agios Pharmaceuticals
|
| |
G1 Therapeutics
|
| |
Radius Health
|
| |
Verastem
|
|
|
Albireo Pharma
|
| |
Ocular Therapeutix
|
| |
Travere Therapeutics
|
| |
Vericel
|
|
Name
|
| |
2022 Annualized
Base Salary ($) |
| |||
David P. Meeker
|
| | | | 652,050 | | |
Hunter C. Smith
|
| | | | 460,000 | | |
Jennifer Chien
|
| | | | 430,000 | | |
Yann Mazabraud
|
| | | | 430,000 | | |
Joseph Shulman
|
| | | | 410,000 | | |
Name
|
| |
2022 Target Bonus
(as a percentage of base salary) |
| |||
David P. Meeker
|
| | | | 65% | | |
Hunter C. Smith
|
| | | | 40% | | |
Jennifer Chien
|
| | | | 40% | | |
Yann Mazabraud
|
| | | | 40% | | |
Joseph Shulman
|
| | | | 40% | | |
Named Executive Officer
|
| |
2022 Target
Bonus |
| |
Actual 2022
Bonus Payout |
| ||||||
David P. Meeker
|
| | | $ | 423,833 | | | | | $ | 505,420 | | |
Hunter C. Smith
|
| | | $ | 184,000 | | | | | $ | 217,000 | | |
Jennifer Chien
|
| | | $ | 172,000 | | | | | $ | 202,000 | | |
Yann Mazabraud
|
| | | $ | 172,000 | | | | | $ | 202,697 | | |
Joseph Shulman
|
| | | $ | 164,000 | | | | | $ | 186,000 | | |
Name
|
| |
Number of Shares
Underlying Stock Options |
| |
Number of RSUs
|
| ||||||
David P. Meeker
|
| | | | 510,000 | | | | | | — | | |
Hunter C. Smith
|
| | | | 97,500 | | | | | | 16,250 | | |
Jennifer Chien
|
| | | | 82,500 | | | | | | 13,750 | | |
Yann Mazabraud
|
| | | | 82,500 | | | | | | 13,750 | | |
Joseph Shulman
|
| | | | 63,750 | | | | | | 10,625 | | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($) |
| |
Stock
Awards ($)(1) |
| |
Option
Awards ($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total
|
| ||||||||||||||||||||||||
David P. Meeker
Chief Executive Officer |
| | | | 2022 | | | | | | 652,050 | | | | | | — | | | | | | — | | | | | | 2,157,300 | | | | | | 505,420 | | | | | | 10,988 | | | | | | 3,325,758 | | |
| | | 2021 | | | | | | 630,000 | | | | | | — | | | | | | 1,164,842 | | | | | | 4,204,200 | | | | | | 450,954 | | | | | | 8,364 | | | | | | 6,458,360 | | | ||
| | | 2020 | | | | | | 262,308 | | | | | | — | | | | | | 918,500 | | | | | | 12,844,897 | | | | | | 207,958 | | | | | | 43,704 | | | | | | 14,277,367 | | | ||
Hunter C. Smith
Chief Financial Officer |
| | | | 2022 | | | | | | 460,000 | | | | | | — | | | | | | 110,500 | | | | | | 412,425 | | | | | | 217,000 | | | | | | 15,200 | | | | | | 1,215,125 | | |
| | | 2021 | | | | | | 435,957 | | | | | | — | | | | | | 576,264 | | | | | | 1,074,938 | | | | | | 210,654 | | | | | | 11,600 | | | | | | 2,309,412 | | | ||
| | | 2020 | | | | | | 416,118 | | | | | | 60,000 | | | | | | 132,000 | | | | | | 1,837,630 | | | | | | 209,595 | | | | | | 7,125 | | | | | | 2,662,468 | | | ||
Jennifer Chien
Executive Vice President, Head of North America |
| | | | 2022 | | | | | | 430,000 | | | | | | — | | | | | | 93,500 | | | | | | 348,975 | | | | | | 202,000 | | | | | | 12,200 | | | | | | 1,086,675 | | |
| | | 2021 | | | | | | 395,000 | | | | | | — | | | | | | 552,376 | | | | | | 931,613 | | | | | | 190,864 | | | | | | 11,600 | | | | | | 2,081,452 | | | ||
| | | 2020 | | | | | | 45,577 | | | | | | 100,000 | | | | | | 100,000 | | | | | | 1,517,540 | | | | | | 49,375 | | | | | | 7,125 | | | | | | 1,819,617 | | | ||
Yann Mazabraud(5)
Executive Vice President, Head of International |
| | | | 2022 | | | | | | 380,643 | | | | | | — | | | | | | 93,500 | | | | | | 348,975 | | | | | | 202,697 | | | | | | 164,090(6) | | | | | | 1,189,905 | | |
| | | 2021 | | | | | | 384,250 | | | | | | — | | | | | | 552,376 | | | | | | 931,613 | | | | | | 190,864 | | | | | | 118,502 | | | | | | 2,177,605 | | | ||
Joseph Shulman
Chief Technical Officer |
| | | | 2022 | | | | | | 410,000 | | | | | | — | | | | | | 72,250 | | | | | | 269,663 | | | | | | 186,000 | | | | | | 12,200 | | | | | | 950,113 | | |
| | | 2021 | | | | | | 386,250 | | | | | | — | | | | | | 516,545 | | | | | | 716,625 | | | | | | 157,223 | | | | | | 11,600 | | | | | | 1,788,243 | | |
Name
|
| |
Grant Date
|
| |
Estimated Future Payouts
Under Non-Equity Incentive Plan Awards(1) |
| |
Estimated Future Payouts Under
Equity Incentive Plan Awards |
| |
All Other
Stock Awards: Number of Shares of Stock or Units(#) |
| |
All Other
Option Awards: Number of Securities Underlying Options(#) |
| |
Exercise or
Base Price of Option Awards ($/Sh) |
| |
Grant Date
Fair Value of Stock and Option Awards ($) |
| ||||||||||||||||||||||||||||||||||||||||||
|
Threshold
($) |
| |
Target
($) |
| |
Maximum
($) |
| |
Threshold
(#) |
| |
Target
(#) |
| |
Maximum
(#) |
| |||||||||||||||||||||||||||||||||||||||||||||||
David P. Meeker
|
| |
—
|
| | | | — | | | | | | 423,833 | | | | | | 752,727 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | 510,000 | | | | | $ | 6.80 | | | | | $ | 2,157,300 | | |
Hunter C. Smith
|
| |
—
|
| | | | — | | | | | | 184,000 | | | | | | 326,784 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | | | | | | | 97,500 | | | | | $ | 6.80 | | | | | $ | 412,425 | | |
| | | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,250 | | | | | | — | | | | | | — | | | | | $ | 110,500 | | |
Jennifer Chien
|
| |
—
|
| | | | — | | | | | | 172,000 | | | | | | 305,472 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | | | | | | | 82,500 | | | | | $ | 6.80 | | | | | $ | 348,975 | | |
| | | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 13,750 | | | | | | — | | | | | | — | | | | | $ | 93,500 | | |
Yann Mazabraud
|
| |
—
|
| | | | — | | | | | | 172,000 | | | | | | 305,472 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | | | | | | | 82,500 | | | | | $ | 6.80 | | | | | $ | 348,975 | | |
| | | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 13,750 | | | | | | — | | | | | | — | | | | | $ | 93,500 | | |
Joseph Shulman
|
| |
—
|
| | | | — | | | | | | 164,000 | | | | | | 291,264 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | | | | | | | 63,750 | | | | | $ | 6.80 | | | | | $ | 269,663 | | |
| | | | | 2/9/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,625 | | | | | | — | | | | | | — | | | | | $ | 72,250 | | |
| | |
Option Awards (2)
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
Name
|
| |
Vesting
Commencement Date |
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market Value
of Shares or Units of Stock That Have Not Vested ($)(1) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) |
| |||||||||||||||||||||||||||
David P. Meeker, M.D.
|
| | | | 11/17/2015(2) | | | | | | 43,621 | | | | | | — | | | | | $ | 4.59 | | | | | | 11/16/2025 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1/6/2017(2) | | | | | | 65,430 | | | | | | — | | | | | $ | 6.05 | | | | | | 02/07/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 6/6/2018(3) | | | | | | 10,000 | | | | | | — | | | | | $ | 34.89 | | | | | | 06/05/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 6/19/2019(3) | | | | | | 15,000 | | | | | | — | | | | | $ | 22.93 | | | | | | 06/18/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 6/17/2020(3) | | | | | | 18,500 | | | | | | — | | | | | $ | 21.37 | | | | | | 06/16/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 7/20/2020(4) | | | | | | 506,250 | | | | | | 393,750 | | | | | $ | 22.53 | | | | | | 07/19/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/11/2021(5) | | | | | | 96,250 | | | | | | 123,750 | | | | | $ | 30.66 | | | | | | 02/10/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 32,992 | | | | | | 960,727 | | | | | | 43,990 | | | | | | 1,280,974 | | |
| | | | | 2/9/2022(5) | | | | | | 95,625 | | | | | | 414,375 | | | | | $ | 6.80 | | | | | | 02/08/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | |
Hunter C. Smith
|
| | | | 7/31/2017(4) | | | | | | 163,094 | | | | | | — | | | | | $ | 6.88 | | | | | | 08/08/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/14/2018(5) | | | | | | 61,000 | | | | | | — | | | | | $ | 25.79 | | | | | | 02/13/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 5/13/2019(5) | | | | | | 65,625 | | | | | | 4,375 | | | | | $ | 29.78 | | | | | | 02/12/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 5/14/2020(5) | | | | | | 56,375 | | | | | | 25,625 | | | | | $ | 17.87 | | | | | | 02/13/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 7/20/2020(5) | | | | | | 7,812 | | | | | | 17,188 | | | | | $ | 22.53 | | | | | | 07/16/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/11/2021(5) | | | | | | 24,609 | | | | | | 31,641 | | | | | $ | 30.66 | | | | | | 02/10/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/11/2021(7) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 7,031 | | | | | | 204,743 | | | | | | | | | | | | | | |
| | | | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,248 | | | | | | 327,542 | | | | | | 14,996 | | | | | | 436,684 | | |
| | | | | 2/9/2022(5) | | | | | | 18,281 | | | | | | 79,219 | | | | | $ | 6.80 | | | | | | 02/08/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/11/2022(7) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,250 | | | | | | 473,200 | | | | | | | | | | | | | | |
Yann Mazabraud
|
| | | | 10/5/2020(8) | | | | | | 50,000 | | | | | | 50,000 | | | | | $ | 22.28 | | | | | | 10/04/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/11/2021(5) | | | | | | 21,328 | | | | | | 27,422 | | | | | $ | 30.66 | | | | | | 02/10/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/11/2021(7) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 6,093 | | | | | | 177,428 | | | | | | | | | | | | | | |
| | | | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,248 | | | | | | 327,542 | | | | | | 14,996 | | | | | | 436,684 | | |
| | | | | 2/9/2022(5) | | | | | | 15,469 | | | | | | 67,031 | | | | | $ | 6.80 | | | | | | 02/08/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/9/2022(7) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 13,760 | | | | | | 400,691 | | | | | | | | | | | | | | |
Jennifer Chien
|
| | | | 11/9/2020(8) | | | | | | 50,000 | | | | | | 50,000 | | | | | $ | 24.29 | | | | | | 11/08/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/11/2021(5) | | | | | | 21,328 | | | | | | 27,422 | | | | | $ | 30.66 | | | | | | 02/10/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/11/2021(7) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 6,093 | | | | | | 177,428 | | | | | | | | | | | | | | |
| | | | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,248 | | | | | | 327,542 | | | | | | 14,996 | | | | | | 436,684 | | |
| | | | | 2/9/2022(5) | | | | | | 15,469 | | | | | | 67,031 | | | | | $ | 6.80 | | | | | | 02/08/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/9/2022(7) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 13,760 | | | | | | 400,691 | | | | | | | | | | | | | | |
Joseph Shulman
|
| | | | 7/27/2020(8) | | | | | | 47,813 | | | | | | 37,187 | | | | | $ | 21.38 | | | | | | 07/26/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/11/2021(5) | | | | | | 16,406 | | | | | | 21,094 | | | | | $ | 30.66 | | | | | | 02/10/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/11/2021(7) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,687 | | | | | | 136,485 | | | | | | | | | | | | | | |
| | | | | 11/9/2021(6) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,248 | | | | | | 327,542 | | | | | | 14,996 | | | | | | 436,684 | | |
| | | | | 2/9/2022(5) | | | | | | 11,963 | | | | | | 51,797 | | | | | $ | 6.80 | | | | | | 02/08/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2/9/2022(7) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,625 | | | | | | 309,400 | | | | | | | | | | | | | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||
Name
|
| |
Number of Shares
Acquired on Exercise (#) |
| |
Value Realized
on Exercise(1) ($) |
| |
Number of Shares
Acquired on Vesting (#) |
| |
Value Realized
on Vesting(2) ($) |
| ||||||||||||
David P. Meeker
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Hunter C. Smith
|
| | | | — | | | | | | — | | | | | | 27,344 | | | | | | 118,119 | | |
Jennifer Chien
|
| | | | — | | | | | | — | | | | | | 2,032 | | | | | | 12,456 | | |
Yann Mazabraud
|
| | | | — | | | | | | — | | | | | | 2,032 | | | | | | 12,456 | | |
Joe Shulman
|
| | | | — | | | | | | — | | | | | | 1,563 | | | | | | 9,581 | | |
Name
|
| |
Benefit
|
| |
Termination
Without Cause or for Good Reason / Cause (no Change in Control) ($) |
| |
Change in Control
(no Termination) ($)(1) |
| |
Termination Without
Cause or for Good Reason / Cause in Connection with a Change in Control ($) |
| |||||||||
David P. Meeker
|
| | Cash | | | | | 652,050 | | | | | | — | | | | | | 978,075 | | |
| | | Equity Acceleration(2) | | | | | — | | | | | | 14,085,364 | | | | | | 14,085,364 | | |
| | | Continued Healthcare | | | | | 20,741 | | | | | | — | | | | | | 31,162 | | |
| | | Total(3) | | | | | 672,824 | | | | | | 14,085,364 | | | | | | 15,094,601 | | |
Hunter C. Smith
|
| | Cash | | | | | 345,000 | | | | | | — | | | | | | 644,000 | | |
| | | Equity Acceleration(2) | | | | | — | | | | | | 3,611,886 | | | | | | 3,611,886 | | |
| | | Continued Healthcare | | | | | 21,114 | | | | | | — | | | | | | 28,153 | | |
| | | Total(3) | | | | | 366,114 | | | | | | 3,611,886 | | | | | | 4,284,039 | | |
Jennifer Chien
|
| | Cash | | | | | 322,500 | | | | | | — | | | | | | 602,000 | | |
| | | Equity Acceleration(2) | | | | | — | | | | | | 3,079,977 | | | | | | 3,079,977 | | |
| | | Continued Healthcare | | | | | — | | | | | | — | | | | | | — | | |
| | | Total(3) | | | | | 322,500 | | | | | | 3,079,977 | | | | | | 3,681,977 | | |
Yann Mazabraud
|
| | Cash | | | | | 226,568 | | | | | | — | | | | | | 226,568 | | |
| | | Equity Acceleration(2) | | | | | — | | | | | | 3,180,477 | | | | | | 3,180,477 | | |
| | |
All Other Payments or Benefits
|
| | | | — | | | | | | — | | | | | | | | |
| | | Total(3) | | | | | 226,568 | | | | | | 3,180,477 | | | | | | 3,407,045 | | |
Joseph Shulman
|
| | Cash | | | | | 307,000 | | | | | | — | | | | | | 574,000 | | |
| | | Equity Acceleration | | | | | — | | | | | | 2,654,047 | | | | | | 2,654,047 | | |
| | | Continued Healthcare | | | | | 15,581 | | | | | | — | | | | | | 20,774 | | |
| | | Total(3) | | | | | 322,581 | | | | | | 2,654,047 | | | | | | 3,248,821 | | |
Year(1)(2)
|
| |
Summary
Compensation Table (SCT) Total for PEO |
| |
Compensation
Actually Paid to PEO(3) |
| |
Average
SCT Total for Non- PEO NEOs |
| |
Average
Compensation Actually Paid to Non-PEO NEOs(3) |
| |
Value of Initial Fixed $100
Investment Based on: |
| |||||||||||||||||||||
|
Total
Shareholder Return |
| |
Net Income
|
| ||||||||||||||||||||||||||||||||
2022
|
| | | | 3,325,758 | | | | | | 23,300,503 | | | | | | 1,110,454 | | | | | | 4,518,216 | | | | | | -2.06 | | | | | | (181,119) | | |
2021
|
| | | | 6,458,360 | | | | | | (10,456,948) | | | | | | 2,069,493 | | | | | | (875,147) | | | | | | -66.43 | | | | | | (69,612) | | |
Year
|
| |
PEO
|
| |
Non-PEO NEOs
|
|
2022 | | | David P. Meeker | | |
Hunter C. Smith, Jennifer Chien, Yann
Mazabraud and Joseph Shulman |
|
2021 | | | David P. Meeker | | |
Hunter C. Smith, Murray Stewart, Jennifer
Chien, Yann Mazabraud and Joseph Shulman |
|
| | |
2022
|
| |
2021
|
| ||||||||||||||||||
| | |
PEO
|
| |
Average for
Other NEO’s |
| |
PEO
|
| |
Average for
Other NEO’s |
| ||||||||||||
Summary Compensation Table Total
|
| | | | 3,325,758 | | | | | | 1,110,454 | | | | | | 6,458,360 | | | | | | 2,089,178 | | |
ADJUSTMENTS(a): | | | | | | | | | | | | | | | | | | | | | | | | | |
Deduction for Amounts reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table(a)
|
| | | | (2,157,300) | | | | | | (437,447) | | | | | | (5,369,042) | | | | | | (1,449,555) | | |
Increase based on ASC 718 Fair Value of Awards
Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End |
| | | | 10,482,921 | | | | | | 2,072,347 | | | | | | 1,452,839 | | | | | | 403,025 | | |
Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date
|
| | | | 1,225,845 | | | | | | 196,045 | | | | | | 264,748 | | | | | | 56,509 | | |
Increase/deduction for Awards Granted during Prior
FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End |
| | | | 9,759,451 | | | | | | 1,489,684 | | | | | | (9,884,565) | | | | | | (1,161,722) | | |
Increase/deduction for Awards Granted during Prior
FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date |
| | | | 663,828 | | | | | | 87,133 | | | | | | (3,379,288) | | | | | | (414,095) | | |
Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End
|
| | | | — | | | | | | — | | | | | | — | | | | | | (398,487) | | |
Increase based on Dividends or Other Earnings Paid
during Applicable FY prior to Vesting Date |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Increase based on Incremental Fair Value of Options/
SARs Modified during Applicable FY |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Adjustments Related to Defined Benefit and Actuarial Pension Plans
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Compensation Actually Paid
|
| | | | 23,300,503 | | | | | | 4,518,216 | | | | | | (10,456,949) | | | | | | (875,147) | | |
Fee Category
|
| |
2021
|
| |
2022
|
| ||||||
Audit Fees
|
| | | $ | 903,571 | | | | | $ | 902,250 | | |
Audit Related Fees
|
| | | | — | | | | | | — | | |
Tax Fees
|
| | | $ | 53,600 | | | | | $ | 107,932 | | |
All Other Fees
|
| | | $ | 3,600 | | | | | $ | 3,600 | | |
Total Fees
|
| | | $ | 960,771 | | | | | $ | 1,013,782 | | |
Name and Address of Beneficial Owner
|
| |
Number of Shares
Beneficially Owned† |
| |
Percentage of Shares
Beneficially Owned |
| ||||||
5% or Greater Stockholders: | | | | | | | | | | | | | |
Entities affiliated with PRIMECAP Management Company(1)
|
| | | | 6,911,142 | | | | | | 12.2 | | |
77 E. Colorado Blvd., 11th Floor
Pasadena, CA 91105 |
| | | | | | | | | | | | |
Entities affiliated with Baker Bros. Advisors LP(2)
|
| | | | 6,354,608 | | | | | | 11.2 | | |
c/o Baker Bros. Advisors LP
860 Washington Street, 3rd Floor New York, NY 10014 |
| | | | | | | | | | | | |
Entities affiliated with Federated Hermes, Inc.(3)
|
| | | | 6,304,482 | | | | | | 11.1 | | |
1001 Liberty Avenue
Pittsburgh, PA 15222-3779 |
| | | | | | | | | | | | |
Entities affiliated with RA Capital Management, LLC(4)
|
| | | | 5,516,067 | | | | | | 9.7 | | |
c/o RA Capital Management, LLC
200 Berkeley Street, 18th Floor, Boston, MA 02116 |
| | | | | | | | | | | | |
The Goldman Sachs Group, Inc.(5)
|
| | | | 5,201,260 | | | | | | 9.2 | | |
200 West Street
New York, NY 10282 |
| | | | | | | | | | | | |
BlackRock, Inc.(6)
|
| | | | 3,723,714 | | | | | | 6.6 | | |
55 East 52nd Street
New York, NY 10055 |
| | | | | | | | | | | | |
Entities affiliated with State Street Corporation(7)
|
| | | | 3,180,698 | | | | | | 5.6 | | |
c/o State Street Corporation
1 Lincoln Street Boston, MA 02111 |
| | | | | | | | | | | | |
Entities affiliated with New Enterprise Associates 13, L.P.(8)
|
| | | | 2,911,349 | | | | | | 5.1 | | |
New Enterprise Associates
1954 Greenspring Drive, Suite 600 Timonium, MD 21093 |
| | | | | | | | | | | | |
Directors and Named Executive Officers: | | | | | | | | | | | | | |
David P. Meeker, M.D.(9)
|
| | | | 1,202,907 | | | | | | 2.1 | | |
Hunter C. Smith(10)
|
| | | | 541,420 | | | | | | * | | |
Jennifer Chien(11)
|
| | | | 124,589 | | | | | | * | | |
Yann Mazabraud(12)
|
| | | | 119,529 | | | | | | * | | |
Joseph Shulman(13)
|
| | | | 105,287 | | | | | | * | | |
Stuart A. Arbuckle(14)
|
| | | | 83,500 | | | | | | * | | |
Name and Address of Beneficial Owner
|
| |
Number of Shares
Beneficially Owned† |
| |
Percentage of Shares
Beneficially Owned |
| ||||||
Camille L. Bedrosian, M.D.(15)
|
| | | | 59,790 | | | | | | * | | |
Jennifer Good(16)
|
| | | | 83,500 | | | | | | * | | |
Christophe R. Jean(17)
|
| | | | 78,500 | | | | | | * | | |
Edward T. Mathers(18)
|
| | | | 84,271 | | | | | | * | | |
David W.J. McGirr(19)
|
| | | | 165,741 | | | | | | * | | |
Lynn A. Tetrault, J.D.(20)
|
| | | | 59,790 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(21)
|
| | | | 2,768,857 | | | | | | 4.7 | | |